Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China
ConclusionsAlfosbuvir plus daclatasvir for 12 weeks was highly effective and safe in Chinese patients infected with HCV genotype 1, 2, 3, or 6, suggesting that this regimen could be a promising option for HCV treatment in China irrespective of genotype.Trial RegistrationClinicalTrial.gov identifier, NCT04070235.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research
More News: China Health | Hepatitis | Hepatitis C | History of Medicine | Infectious Diseases | Study | Virology